Epsilon-Gamma-Delta-Beta-Thalassemia

Article written and reviewed by Dr Luca Moretti

Epsilon-gamma-delta-beta-thalassemia (εγδβ-thalassemia) is an extremely rare hemoglobinopathy caused by an extensive deletion of the beta-globin cluster on chromosome 11, which may include HBE1, HBG2, HBG1, HBD and HBB and, in some families, regulatory regions or adjacent genes. Reported cases are mainly heterozygous and sometimes de novo: the unaffected allele therefore continues to produce beta-like globins.

Etiology, Genetics and Pathophysiology

The deletion silences the entire beta-globin cluster on the affected allele during embryonic, fetal and adult life. Clinical variability does not correlate reliably with the extent of the deletion and depends on genetic modifiers, regulatory features and other incompletely defined factors. In the fetus and neonate, when demand for gamma chains is high, the normal allele may not fully compensate for loss of the other allele, causing anemia that may be severe. With the physiologic switch from gamma-chain to beta-chain synthesis, the condition may improve spontaneously during the first months of life.

Alpha-globin gene status may significantly modify the phenotype: in particular, alpha triplication has been associated with marked worsening of fetal and neonatal anemia, up to hydrops fetalis and the need for intrauterine transfusions.

Clinical Presentation

The most characteristic manifestation is prenatal or neonatal anemia, sometimes associated with hydrops, heart failure, hepatosplenomegaly, jaundice or a need for transfusion. Severity is variable, and adverse perinatal outcomes have also been reported. In survivors, anemia often improves during the first months; later in life, mild microcytosis and hypochromia may persist, or the complete blood count may be nearly normal. Pregnancy or other states of increased erythropoietic demand may make the phenotype more apparent.

Diagnosis and Investigations

The disorder should be suspected in unexplained fetal or neonatal anemia, especially when accompanied by microcytosis and a compatible family history. The hemoglobin-fraction profile is not diagnostic by itself and may become nonspecific after the neonatal period. Confirmation requires detection of beta-globin-cluster deletions by MLPA, genomic array or other copy-number and breakpoint methods. Parental testing distinguishes inherited from de novo deletions and supports accurate reproductive counseling.

Treatment and Prognosis

Management is supportive and depends on severity. Intrauterine or neonatal transfusions, treatment of hyperbilirubinemia and cardiopulmonary support may be required. Chronic transfusion therapy is not indicated when anemia regresses; iron must be monitored only after repeated transfusions or when other risk factors are present. Prognosis is determined mainly by prenatal and neonatal severity and by possible involvement of contiguous genes.

Complications

Documented complications include severe fetal or neonatal anemia, hydrops, high-output heart failure, hyperbilirubinemia and perinatal death. Iron overload may occur in patients receiving repeated transfusions; in particular circumstances, ineffective erythropoiesis and concomitant conditions that alter iron homeostasis may also contribute. Neutropenia, immunodeficiency, chronic marrow expansion and permanent transfusion dependence are not typical features of the isolated heterozygous form.

References
1. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge University Press. 2nd ed. 2009.
2. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Blackwell Science. 4th ed. 2001.
3. Bain BJ. Haemoglobinopathy Diagnosis. Wiley-Blackwell. 3rd ed. 2020.
4. Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013;3(2):a011684.
5. Game L, Bergounioux J, Close JP, Marzouka BE, Thein SL. A novel deletion causing (epsilon gamma delta beta)0 thalassaemia in a Chilean family. Br J Haematol. 2003;123(1):154–159.
6. Shalev H, Landau D, Pissard S, et al. A novel epsilon gamma delta beta thalassemia presenting with pregnancy complications and severe neonatal anemia. Eur J Haematol. 2013;90(2):127–133.
7. Rooks H, Clark B, Best S, et al. A novel 506 kb deletion causing epsilon gamma delta beta thalassemia. Blood Cells Mol Dis. 2012;49(3-4):121–127.
8. Bain BJ, Daniel Y, Henthorn J, de la Salle B, Hogan A, Roy NBA, et al.; British Society for Haematology. Significant haemoglobinopathies: A guideline for screening and diagnosis. Br J Haematol. 2023;201(6):1047-1065.
9. Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3(5):a011700.
10. Old JM. Haemoglobinopathies and thalassaemias. Medicine. 2020;48(8):511–519.